American Society of Anesthesiologists

Fig. 3. Release of thromboxane (TX) B2(± SD), a stable metabolite of TXA2, into the perfusate of isolated rabbit lungs in which leukocyte activation was performed with 10−6M N -formyl-Met-Leu-Phe (fMLP) in the absence or in presence of pancreatitis-associated protein (PAP; 260 μg/l, n = 9; 500 μg/l, n = 6). * P < 0.05 vs. fMLP, ** P < 0.01 vs. fMLP, analysis of variance. PAP reduced TXB2generation in a dose-dependent manner.

Fig. 3. Release of thromboxane (TX) B²(± SD), a stable metabolite of TXA², into the perfusate of isolated rabbit lungs in which leukocyte activation was performed with 10⁻⁶M N -formyl-Met-Leu-Phe (fMLP) in the absence or in presence of pancreatitis-associated protein (PAP; 260 μg/l, n = 9; 500 μg/l, n = 6). * P < 0.05 vs. fMLP, ** P < 0.01 vs. fMLP, analysis of variance. PAP reduced TXB²generation in a dose-dependent manner.

This Feature Is Available To Subscribers Only